[New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment].
| Autor: | Croizier C; CHU d'Estaing, service de thérapie cellulaire et d'hématologie clinique adulte, 63000 Clermont-Ferrand, France. Electronic address: ccroizier@chu-clermontferrand.fr., Van de Wyngaert Z; AP-HP, hôpital Saint-Antoine, Sorbonne université, hématologie clinique et thérapie cellulaire, Inserm UMRs 938, 75012 Paris, France. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Bulletin du cancer [Bull Cancer] 2022 Feb; Vol. 109 (2), pp. 113-114. Date of Electronic Publication: 2022 Jan 19. |
| DOI: | 10.1016/j.bulcan.2021.10.007 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|